A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms The LENKYN Trial

Most Recent Events

26 Nov 2024 Planned End Date changed from 28 Feb 2027 to 31 Dec 2025.
05 Aug 2024 Planned End Date changed from 28 Feb 2026 to 28 Feb 2027.
05 Aug 2024 Planned primary completion date changed from 31 Jul 2024 to 31 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight